You're making the right move. I've been with them for years and they have torn down (management\pipeline) and now are building up the company on firm foundation. CUDC907 is a winner and already has great results for the public to see that is being overlooked by many. The abstract has been submitted for ASCO. When I consider what a fair market cap and PT for the company should be I take into account that it is on schedule this year to have 2 drugs having IND's submitted\ into P1 (recent alliance with Aurigene); another drug, CUDC 427 in P1; another drug in a P1/2 trial CUDC 305; another drug in a P1 (solids) & P2/3 trial, CUDC 907; and a drug, Erivedge, that is commercialized with a nice growth curve along with being in various P2 trials. Now this is no ACAD but I'd suggest looking at their pipeline chart ((((http://www.acadia-pharm.com/pipeline/)))) and their market cap of > $3B or an INFI with a market cap of > $700M ((((( http://www.infi.com/research-development/pipeline/))))). I do know Curis's pipeline chart will be stronger than those two and have a drug on the market. So I'm thinking it is fair to say they fall between those 2 mc #'s, perhaps half way or a bit more? So maybe a bit north of $1.3B? Just using that crude analysis but logical, that would give them an approx. pps of $12 - $13 by end of year or before. Just something to consider. Interesting how close that comes to RBC's recent upside PT of $14........."
News 
Market Data 
Discover 
